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ABSTRACT
The pharmacokinetics of cefepime (20 mg/kg) were studied following intramuscular administration of 
cefepime alone, co-administered with ketoprofen (3 mg/kg) and in a febrile state (Escherichia coli LPS induced) 
in sheep. The concentration of cefepime in the serum was detected by High Performance Liquid Chromatography. 
Following single dose intravenous administration of cefepime, elimination half life (2.50 ± 0.05 h), the area 
under the curve (143.48± 7.36 μg.h/mL), body clearance (0.14 ± 0.01 L/h/kg) and volume of distribution (0.51 
± 0.03 L/kg) were determined. Following a single dose intramuscular administration of cefepime alone, peak 
serum concentration (28.76 ± 0.54 μg/mL) was obtained at 0.75 h. The absorption half life (t1/2Kα), volume of 
distribution (Vdarea), total body clearance (ClB) and elimination half life (t1/2β) of cefepime were 0.16 ± 0.01 h, 
1.02 ± 0.08 L/kg, 0.13 ± 0.01 L/h/kg and 5.31 ± 0.23 h, respectively. Following co-administration of ketoprofen 
(30.74 ± 1.22 μg/mL) and in a febrile condition, a higher peak serum concentration of cefepime (39.68 ± 
1.13 μg/mL) was observed at 0.75 h and 1 h, respectively. However, no signifi cant changes were reported in 
other pharmacokinetic parameters following co-administration of cefepime with ketoprofen. In a febrile state, 
absorption half life, area under the curve and bioavailability were signifi cantly increased while the volume of 
distribution and clearance of cefepime were signifi cantly decreased following intramuscular administration. 
Cefepime pharmacokinetic data (20 mg/kg) generated from the present study suggest that the drug may be 
administered with ketoprofen, and in febrile conditions in sheep, the drug may be given intramuscularly at 24 h 
intervals to combat susceptible bacterial infections.
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Introduction
Antibacterial and NSAIDs are used most frequently in multiple drug prescriptions. It 
is well documented that concurrently administered drugs may alter the pharmacokinetics 
of one or both drugs (HARDMAN and LIMBIRD, 2001). Cefepime is a semi-synthetic 
broad spectrum fourth generation cephalosporin antibiotic, with a modifi ed zwitterionic 
structure that allows more favorable penetration into the bacterial cells, higher affi nity 
for its molecular target (PBP3) and reduced susceptibility to β-lactamases (DEL RIO 
et al., 2008). Cefepime can be used for infections that are resistant to third generation 
cephalosporins and for respiratory, urinary, intra-abdominal and cutaneous infections 
(RULE et al., 2004). Cefepime is considered a broad spectrum drug and shows excellent 
activity against Escheria coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and 
Staphylococcus spp. (BARRADELL and BRYSON, 1994). Ketoprofen is routinely used as 
a non-steroidal anti-infl ammatory, analgesic and antipyretic agent in veterinary practice 
(BOOTHE, 1995). The pharmacokinetics of cefepime administered as a single drug have 
been investigated in healthy ewes and calves (ISMAIL, 2005a and 2005b), buffalo calves 
(JOSHI and SHARMA, 2009), dogs (STAMPLEY et al., 1992), horses (GUGLICK et al., 1998), 
neonatal foals (GARDNER and PAPICH, 2001) and goats (RULE et al., 2004). 
However, there is no information available on the infl uence of co-administration of 
ketoprofen and a febrile state on the pharmacokinetics of cefepime in animals. Given the 
possibility of interaction of ketoprofen and to discover the pharmacokinetics of cefepime 
in sheep in a febrile state, this study was undertaken to determine the effect of ketoprofen 
and a febrile condition on the pharmacokinetics of cefepime in sheep. 
Materials and methods
Experimental animals. The experiment was conducted on six healthy adult (3-4 years 
of age) Patanwadi sheep, weighing 25-30 kg. Each sheep was housed in a separate pen 
and provided with a standard ration and water ad libitum. The sheep were kept under 
constant observation for two weeks before the commencement of the experiment and 
subjected to clinical examination to exclude the possibility of disease. The experimental 
protocol was approved by the Institutional Animal Ethics Committee.
Drug and chemicals. Cefepime technical grade powder was procured from 
Aurobindo Pharma, Hyderabad. Cefepime hydrochloride powder (1 g Biopime®; Biochem 
pharmaceutical Industries Ltd., Mumbai) and ketoprofen injection (Neoprofen®; RFCL 
Limited, Uttarakhand) were purchased on the local market. Water, Acetonitrile, Acetic 
acid (HPLC grade), Sodium Acetate (AR grade), Perchloric acid were purchased from 
Merck India Ltd., Mumbai, India.
Drug administration and sample collection. All six animals were randomly allocated 
to receive either an intravenous or an intramuscular injection of cefepime at a dose rate of 
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20 mg/kg. A washout period of 2 weeks was observed between treatments. An intravenous 
injection of cefepime was administered in the left jugular vein. Blood samples (5 mL) were 
collected through an intravenous catheter (Venfl on, 22 × 0.9 × 25 mm) fi xed in the contra-
lateral jugular vein, in glass test tubes prior to injection and at 2, 5, 10, 15, 30 min and 1, 2, 
4, 8, 12, 18, 24 and 36 h after intravenous administration. The intramuscular injection of 
cefepime (20 mg/kg) was administered in the left deep gluteal muscles, while ketoprofen 
was administrated deeply intramuscularly at a dose rate of 3 mg/kg in the contra-lateral 
gluteal muscle. Blood samples (5 mL) were collected, before administration and at 5, 
10, 15, 30 min and 1, 2, 4, 8, 12, 18, 24 and 36 h after intramuscular administration of 
cefepime alone or in combination with ketoprofen. A febrile state was induced in the 
sheep by injecting lipopolysaccharide (LPS) of Escherichia coli at a dose rate of 0.2 
μg/kg body weight intravenously (VERMA and ROY, 2006). LPS was again injected at a 
dose rate of 0.1 and 0.05 μg/kg at 12 h and 24 h from the fi rst dose of LPS to maintain 
the febrile state up to 36 h. Sheep were monitored for any adverse reactions during the 
entire study period. Blood samples were allowed to clot and the serum was harvested by 
centrifugation at 1957 g for 15min. The serum samples were stored at -40 oC and analyzed 
within 24 h for determination of cefepime concentration. 
Analytical assay of cefepime and pharmacokinetic analysis. Cefepime concentration 
in serum samples was determined by reverse-phase High Performance Liquid 
Chromatography (HPLC) after extraction, using a reported assay (GARDNER and PAPICH, 
2001) with minor modifi cations. High Performance Liquid Chromatography (HPLC) 
apparatus of Laballiance (USA) comprising a quaternary gradient delivery pump (model 
AIS 2000), UV detector (model 500) and C18 column (Thermo ODS: 250 × 4.6 mm ID) 
were used. Pharmacokinetic data integration was done by the software Clarity (Version 
2.4.0.190). 
Serum (500 μL) was deproteinized by addition of perchloric acid (0.8 M) and 
vortexed for one minute. This was followed by centrifugation at 1957 g for 15 minutes. 
An aliquot of supernatant was collected in a clean vial and 20 μL injected into a loop of 
the HPLC system. The mobile phase was a mixture of 0.2 M sodium acetate (3.2%), 0.2 
M acetic acid (2.2%), acetonitrile (10.0%) and HPLC water (84.6%) having pH 5.1. The 
mobile phase was fi ltered by a 0.45μ fi lter and pumped into the column at a fl ow rate of 
1.5mL/min at ambient temperature. The effl uent was monitored at 257 nm wavelength.
A calibration curve was prepared daily for drug concentrations ranging from 0.5 to 
200 μg/mL. The assay was sensitive (LLOD: 0.5 μg/mL), reproducible and linearity was 
observed from 0.5 to 200 μg/mL (r2 = 0.99). Precision and accuracy were determined 
using quality control (QC) samples at concentrations 1, 5, 50 μg/mL (5 replicates each 
per day). The intraday and inter-day coeffi cients of variation for 5 QC samples were 
satisfactory, with relative deviations (RSD) of less than 4%. Various pharmacokinetic 
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parameters were calculated from the serum concentration of cefepime using the software 
PK solution (version 2.0). The bioavailability (F) was calculated using the following 
formula:
            
AUC (i.m.)      DOSE (i.v.)
F% =  __________ × ________
            AUC (i.v.)       DOSE (i.m.)
Statistical analysis. Cefepime serum concentration and pharmacokinetic parameters 
of different treatment groups were compared by the Student’s t test using SPSS software 
(version 12.0.1).
Results
Serum cefepime concentrations at different time intervals following intramuscular 
injection alone or co-administered intramuscularly with ketoprofen and under a febrile 
state in sheep is presented as a semi logarithmic plot in Fig. 1. 
Time (h)
Fig. 1. Semilogarithmic plot of serum concentrations of cefepime after intramuscular 
administration (20 mg/kg) in healthy, ketoprofen- treated (3 mg/kg) and febrile sheep (LPS-
induced). Each point represents a mean of six animals.
The serum concentration of cefepime at 2 min after intravenous administration 
was 126.09 ± 2.99 μg/mL, which rapidly declined to 28.71 ± 1.67 μg/mL at 1 h and 
was detected up to 12 hrs (1.24 ± 0.09 μg/mL). Following intramuscular injection of 
cefepime alone, the serum concentration of cefepime at 5 min was 10.09 ± 0.62 μg/
mL, which gradually increased and reached the peak concentration (28.76 ± 0.54 μg/mL) 
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107.11 ± 4.66%. On concurrent administration of ketoprofen and cefepime, the initial 
serum concentration of cefepime at 5 min was 11.10 ± 1.33 μg/mL, which increased to 
attain the peak serum concentration (30.74 ± 1.22 μg/mL) at 45 min. The bioavailability 
of cefepime following intramuscular administration in ketoprofen treated sheep was 
112.95 ± 7.53%. In a febrile condition, serum cefepime concentration following 
intramuscular injection was 11.73 ± 0.83 μg/mL at 5min, and attained peak concentration 
at 1 h (39.68 ± 1.13 μg/mL). The bioavailability of cefepime following intramuscular 
administration in a febrile condition in sheep was 148.20 ± 11.64%. Drug levels above 
the minimum inhibitory concentration (MIC) were detected in serum up to 18 h following 
a single dose intramuscular administration of cefepime alone and co-administrated with 
ketoprofen, while in the febrile state it was maintained up to 24 h in sheep. Various 
kinetic determinants that describe the absorption and elimination pattern of cefepime 
after intravenous injection and intramuscular administration, either used alone or in 
combination with ketoprofen and in a febrile state were calculated and are presented in 
Table 1. Following intramuscular administration of cefepime (20 mg/kg) in sheep either 
alone, co-administered with ketoprofen (3 mg/kg) or under a febrile condition, no adverse 
effects or toxic manifestations were observed. 
Table 1. Pharmacokinetic parameters of cefepime following a single dose intravenous injection 
(20 mg/kg body weight) and intramuscular administration (20 mg/kg body weight) alone, 
simultaneously with ketoprofen (3 mg/kg body weight) and in a febrile condition in sheep 














Ka /h - 4.64 ± 0.56 3.15 ± 0.11 3.06 ± 0.34
Β /h 30.440 ± 1.96 0.13 ± 0.01 0.13 ± 0.01 0.13 ± 0.01
t1/2kα h - 0.16 ± 0.01 0.22 ± 0.01* 0.24 ± 0.02*
t1/2β h 2.50 ± 0.05 5.31 ± 0.23 5.22 ± 0.20 5.50 ± 0.25
Cmax μg/mL - 28.76 ± 0.54 30.74 ± 1.22* 39.68 ± 1.13**
Tmax h - 0.75 ± 0.00 0.75 ± 0.00 1.00 ± 0.0
AUC0-∞ μg.h/mL 143.48± 7.36 153.63 ± 10.16 162.37 ± 14.47 221.67 ± 15.42*
AUMC μg.h2/mL 397.77 ± 27.42 921.31 ± 84.21 1013.18 ± 116.63 1464.11 ± 185.12
Vdarea L/kg 0.51 ± 0.03 1.02 ± 0.08 0.97 ± 0.1 0.73 ± 0.04*
ClB L/h/kg 0.14 ± 0.01 0.13 ± 0.01 0.13 ± 0.01 0.09 ± 0.01*
MRT h 2.76 ± 0.05 5.95 ± 0.18 6.17 ± 0.19 6.48 ± 0.38
F % - 107.11 ± 4.66 112.95 ± 7.53 148.20 ± 11.64 
*Signifi cant at P<0.05, **Signifi cant at P<0.01 when compared with respective values of cefepime alone (IM) 
treated sheep. Ka: Absorption rate constant, Β: Zero-time intercept of elimination phase, t1/2ka: Absorption half life, 
t1/2β: Elimination half life, Cmax: Maximum drug concentration, Tmax: Time of maximum observed concentration 
in serum, AUC0-α: Area under the curve, AUMC: Area under fi rst moment of curve, Vdarea: Apparent volume of 
distribution, ClB: Total body clearance, MRT: Mean residence time , F: Bioavailabilty.
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Discussion
A concentration of 0.004 - 1.0 μg/mL of plasma has been reported as the MIC for 
cephalosporins with various pathogens (HARDMAN and LIMBIRD, 2001). Peak serum 
cefepime concentration (Cmax) observed in ketoprofen co-administrated and febrile 
sheep was signifi cantly higher than peak concentrations observed in sheep treated with 
cefepime alone. A similar signifi cant increase in peak plasma levels of ceftizoxime 
following concomitant intramuscular administration of paracetamol with ceftizoxime has 
been observed in cross-bred calves (SINGH et al., 2008). A signifi cant increase in peak 
serum concentrations of cefazolin at 1, 2, 4 and 6 hours after intramuscular administration 
of phenylbutazone was also reported in rabbits (CARBON et al., 1981). Enhanced 
concentrations of cefotiam, cefmenoxime and ceftriaxone were observed following 
concomitant administration of diclofenac sodium in rabbits (JOLY et al., 1988). Similarly 
in a febrile state a signifi cant increase has been reported in peak serum concentrations 
following intramuscular administration of cefepime in rabbits (GOUDAH et al., 2006). 
However, a decrease in maximum drug concentration has been reported following 
intramuscular administration of cefazolin in febrile goats (ROY et al., 1994). 
Following intramuscular administration of cefepime with ketoprofen in sheep, 
a signifi cant increase in absorption half life was observed. However none of the 
other pharmacokinetic parameters were signifi cantly altered in comparison to sheep 
administered cefepime alone. Cefmenoxime’s pharmacokinetic parameters remained 
unchanged following concurrent administration of diclofenac sodium with cefmenoxime 
in rabbits (JOLY et al., 1988), which supports the results of our study. Similarly no 
signifi cant alterations in elimination rate constants and elimination half life were observed 
following coadministration of phenylbutazone and cefazolin in rabbits (CARBON et al., 
1981). However, a signifi cant increase in the area under the curve, and concentration 
and elimination half life have been reported following concomitant administration of 
paracetamol with ceftizoxime in crossbred calves (SINGH et al., 2008). A signifi cantly 
longer elimination half-life of cefazolin was also reported following co-administration 
with phenylbutazone in rabbits (CARBON et al., 1981). 
 Following intramuscular administration in a febrile condition in sheep, absorption 
half life, area under the curve and bioavailability were signifi cantly increased, while 
volume of distribution and body clearance were found to be signifi cantly decreased 
compared to non-febrile cefepime treated sheep. The lower volume of distribution in 
febrile sheep was also refl ected in the signifi cantly higher peak concentration. Moreover, 
bioavailability was also found to be greater than 100% which may be due to sequestration 
of cefepime at the injection site. However, values of elimination half life, area under 
fi rst moment of curve and mean residence time were not signifi cantly altered following 
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intramuscular administration of cefepime in febrile compared to non-febrile sheep. The 
fi ndings indicate that administration of lipopolysaccharide modulates the elimination of 
the drug, which could be due to organ (renal and hepatic) modifications caused by the toxin. 
Endotoxin induces toxic and adverse effects on the kidneys, including direct vascular 
damage to the endothelium and platelet aggregation in renal glomerular capillaries. It 
also produces some functional changes including decrease in the renal blood flow and 
glomerular filtration rate and changes in the intra-renal hemodynamics (JERNIGAN et 
al., 1988; HASEGAWA et al., 1999). It is probable that the decrease in glomerular filtration 
rate induced by endotoxin plays an important role in the decrease of body clearance of 
drugs widely eliminated by the renal route, including cefepime. In comparison to this 
experiment, varied results were found, such as a signifi cant increase in the area under the 
fi rst moment of the curve, the area under the curve, mean residence time and signifi cant 
shorter elimination half life following intramuscular administration of cefepime in febrile 
rabbits (GOUDAH et al., 2006). In another study, signifi cantly lower body clearance and 
higher volumes of distribution after a single intravenous administration of cefepime 
(10 mg/kg) were found in febrile cross-bred calves (PAWAR and SHARMA, 2008). A 
signifi cant increase in elimination half life and volume of distribution, and a signifi cant 
decrease in the value of the area under the curve following intramuscular administration 
of cefazolin in febrile goats were also reported (ROY et al., 1994). However signifi cant 
higher body clearance and signifi cant lower volume of distribution were reported after a 
single intravenous administration of ceftriaxone in febrile buffalo calves (DARDI et al., 
2005). No signifi cant alterations in elimination half life and body clearance were found 
after a single intravenous administration of cefepime (10 mg/kg) in febrile buffalo calves 
(JOSHI and SHARMA, 2009). Variations in the pharmacokinetics of cefepime and other 
cephalosporins when given with NSAIDs and in a febrile condition have been observed 
in many experiments that may be due to differences in the chemistry of drugs and species 
difference. 
It may be concluded that Ketoprofen may be successfully co-administrated with 
cefepime for combating infl ammatory conditions without alterations of the dosage 
regimen of cefepime. In febrile conditions the cefepime concentrations was maintained 
above MIC for a longer period (24 h), hence favoring the use of cefepime in infectious 
diseases of sheep. 
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SAŽETAK
Istražena je farmakokinetika cefepima (20 mg/kg) nakon njegove intramuskularne primjene s ketoprofenom 
(3 mg/kg) u tijeku vrućice u ovaca izazvane lipopolisaharidima bakterije Escherichia coli. Koncentracija 
cefepima u serumu bila je određivana tekućinskom kromatografi jom. Nakon jednokratne intravenske primjene 
poluživot njegova izlučivanja iznosio  je 2,50 ± 0,05 h, površina ispod koncentracijske krivulje  bila je 143,48 
± 7,36 μg.h/mL, ukupni tjelesni klirens iznosio je 0,14 ± 0,01 L/h/kg, a volumen raspodjele 0,51 ± 0,03 L/kg. 
Nakon jednokratne intramuskularne primjene samo cefepima vršna koncentracija u serumu iznosila je 28,76 ± 
0,54 μg/mL nakon 0,75 h. Poluživot apsorpcije (t1/2Kα) iznosio je 0,16 ± 0,01 h, volumen raspodjele (Vdarea) 1,02 
± 0,08 L/kg, ukupni klirens iz organizma (ClB) 0,13 ± 0,01 L/h/kg  te poluživot izlučivanja (t1/2β) 5,31 ± 0,23 h. 
Nakon istodobne primjene ketoprofena (30,74 ± 1,22 μg/mL) u uvjetima izazvane vrućice ustanovljena je veća 
vršna koncentracija cefepima (39,68 ± 1,13 mg/mL) u razdoblju od  0,75 h odnosno 1 sata. Vrijednosti ostalih 
farmakokinetičkih pokazatelja nisu se značajno promijenile poslije istodobne primjene cefepima s ketoprofenom. 
Poluživot apsorpcije, površina ispod koncentracijske krivulje i biološka raspoloživost bili su značajno povišeni, 
dok su volumen raspodjele i klirens cefepima bili značajno sniženi nakon intramuskularne primjene u febrilnih 
životinja. Farmakokinetičke značajke cefepima (20 mg/kg) proizašle iz ovog istraživanja upućuju na zaključak 
da se on u ovaca može primijeniti s ketoprofenom i u febrilnim stanjima. Može se primijeniti intramuskularno u 
razmaku od 24 sata za liječenje bolesti uzrokovanih bakterijama osjetljivima na cefepim.  
Ključne riječi: farmakokinetika, cefepim, ketoprofen, vrućica, ovca________________________________________________________________________________________
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